James (Jay) E. Bradner, M.D.

James (Jay) E. Bradner, M.D., joined Novartis in January 2016 and became President of the Novartis Institutes for BioMedical Research (NIBR) and a member of the Executive Committee of Novartis on March 1, 2016.

Prior to joining Novartis Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute. He was also Associate Director of the Center for the Science of Therapeutics at the Broad Institute of MIT and Harvard. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 130 scientific publications and 30 United States patent applications.

Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School. He completed his residency in Medicine at Brigham & Women's Hospital and fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society of Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

Focus on the patient, follow the science

At the earliest stages of Research, our drug discovery priorities are determined by patient need and sound science – not the potential market size of a medicine.